For which indications are 177lu Dotatate peptide receptor radionuclide therapy approved by the FDA? - Hormone Harmony Clinic

177Lu Dotatate (Lutathera) is a radiolabeled somatostatin analog peptide approved by the FDA for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adults. Specifically, it is indicated for:

Key details: The approval of 177Lu Dotatate was based on the pivotal NETTER-1 phase III trial which demonstrated: Other key points: In summary, 177Lu Dotatate enables targeted radionuclide treatment of inoperable, progressive somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors. Its approval provides an important new therapeutic option for these patients.
If you or a loved one has been diagnosed with a neuroendocrine tumor, the caring physicians at Hormone Harmony Clinic offer cutting-edge services including advanced imaging, pathology reviews, genetic testing, and personalized treatment plans involving surgery, radiologic procedures, and systemic therapies. Speak to our specialists today to discuss your individual needs and health goals.

Get Free Consultation